Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 박은애 | * |
dc.contributor.author | 김경효 | * |
dc.contributor.author | 김한울 | * |
dc.date.accessioned | 2016-08-28T12:08:54Z | - |
dc.date.available | 2016-08-28T12:08:54Z | - |
dc.date.issued | 2011 | * |
dc.identifier.issn | 1328-8067 | * |
dc.identifier.other | OAK-7736 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/221749 | - |
dc.description.abstract | Background: Although MMR vaccine is widely used in Korea, there are limited studies on the currently used vaccines. We evaluated the immunogenicity and safety of MMR vaccines in Korean children. Methods: For first and second dose immunization, children aged 12-23 months and 4-6 years were enrolled. All subjects received a single dose of either Priorix™ (Glaxo Smithkline Biologicals, Rixensart, Belgium) or MMRII® (Merck & Co., Inc., West Point, PA, USA). Pre- and postvaccine sera were collected from all participants. Antibody levels were determined by ELISA (Enzygnost®; Dade Behring, Schwalbach, Germany). Safety monitoring included local adverse events for 5 days and systemic adverse events for 42 days following vaccination. Results: One hundred twenty-one subjects were enrolled in the 12-23 months age group and 39 in the 4-6 years age group. The seroconversion rate in the 12-23 months age group was 97.9-100.0% for measles, 85.1-88.9% for mumps and 100.0% for rubella. All children 4-6 years of age previously seronegative showed seroconversion for measles, mumps and rubella. Local adverse events were reported in 8.3-16.1% (12-23 months age) and 27.8-31.6% (4-6 years age), and 40.0-48.2% (12-23 months age) and 42.1-61.1% (4-6 years age) experienced at least more than 1 systemic adverse reaction. No vaccine-related serious adverse events were reported. Among the same age groups, there was no significant difference in adverse events between the two vaccines. Conclusion: The MMR vaccines are safe and show good immunogenic responses in children. These data will be invaluable when we introduce diverse vaccines in the following future. © 2011 Japan Pediatric Society. | * |
dc.language | English | * |
dc.title | Reappraisal of MMR vaccines currently used in Korea | * |
dc.type | Article | * |
dc.relation.issue | 3 | * |
dc.relation.volume | 53 | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.startpage | 374 | * |
dc.relation.lastpage | 380 | * |
dc.relation.journaltitle | Pediatrics International | * |
dc.identifier.doi | 10.1111/j.1442-200X.2010.03244.x | * |
dc.identifier.wosid | WOS:000292201600016 | * |
dc.identifier.scopusid | 2-s2.0-79959769580 | * |
dc.author.google | Lee H. | * |
dc.author.google | Kim H.W. | * |
dc.author.google | Cho H.K. | * |
dc.author.google | Park E.A. | * |
dc.author.google | Choi K.M. | * |
dc.author.google | Kim K.-H. | * |
dc.contributor.scopusid | 박은애(14424551500) | * |
dc.contributor.scopusid | 김경효(35448653000) | * |
dc.contributor.scopusid | 김한울(43161180100) | * |
dc.date.modifydate | 20240301081003 | * |